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In this study, a new and rapid 
spectrofluorometry method was developed for 
determination of atenolol in pure and pharmaceutical 
preparation. The solvent system and wavelength of 
detection were optimized in order to maximize the 
sensitivity of the proposed method. Parameters such as 
linearity, precision, accuracy, specificity, stability, limit 
of detection and limit of quantification were studied 
according to the International Conference on 
Harmonization  (ICH) Guidelines. The linearity was 
established between the concentration range of 50-
4000 ng/mL. The intra- and inter-day relative standard 
deviation (RSD) was less than 2.97%. Limits of detection 
and quantification were determined as 15.2 and 
46.1 ng/mL, respectively. The mean recovery value of 
atenolol was 99.3% for pharmaceutical preparation. The 
method was applied for the quality control of commercial 
atenolol dosage form to quantify the drug and to check 
the formulation content uniformity.      
































        β-blockers constitute one of the most frequently 
prescribed groups of cardiovascular drugs. They are 
competitive antagonists at β-adrenergic receptor sites and 
are used in the management of cardiovascular disorders, 
such as hypertension, angina pectoris, cardiac 
arrhythmias and myocardial infarction1. 
      Atenolol (Fig-1), [(4-2–hydroxy-3–isopropyl-
aminopropoxy) phenylacetamide], is a cardioselective β-
blocker. It is reported to lack intrinsic sympathomimetic 
activity and membrane-stabilising properties. It may be 
used alone or concomitantly with other antihypertensive 
agents including thiazide-type diuretics, hydralazine, 
prazosin and α-methyldopa2.  
      Several methods have been reported for the 
determination of atenolol including first-order derivative 
spectrophotometry3-5, high performance liquid 
chromatography6-9, voltametry10, potentiometry11 and 
spectrofluorometry12 in pharmaceutical preparations.  
In this study, we wanted to develop a new 
spectrofluorometric method for the determination of 
atenolol in pharmaceutical preparation. The method was 
aimed at developing an easy and rapid assay method for 
atenolol without any time consuming sample preparation 
steps for routine analysis, to be adopted in quality control 
and drug testing laboratories, and at the same time ensure 
satisfactory recovery during drug determination from 
pharmaceutical formulation.  
In the proposed method, there is no need to 
extract the drug from the formulation excipient matrix 
thereby decreasing the error in quantitation. Formulation 
sample can be directly used after dissolving and filtration. 
The developed method was used to determine the total 
drug content in commercially available tablets of 
atenolol.  







  Atenolol standard and Tensinor tablet (100 mg) 
were kindly donated from Abdi Ibrahim Pharmaceutical 
Industry (Istanbul, Turkey).  
Instrument: 
All fluorescence measurements were done on a 
SHIMADSU RF-5301 PC spectrofluorometer equipped 
with a 150 W Xenon lamp. Experimental parameters 
were slit width 5.0 nm, exc=276 nm and em=296 nm. 
Preparation of the standard and quality control 
solutions:   
The stock solution of atenolol was prepared in 
methanol to a concentration of 50 ng/mL and kept stored 
at +4 C. Standard solutions were prepared as 50-
4000 ng/mL (50, 125, 250, 500, 1000, 2000, 3000 and 
4000 ng/mL). The quality control (QC) samples were 
separately prepared at the concentrations of 100, 750 and 
3500 ng/mL.   
 
Procedure for pharmaceutical preparation: 
The average tablet mass was calculated from 
the mass of 10 tablets of Tensinor (100 mg atenolol 
tablet, which was composed of atenolol and some 
commen excipients). They were then finely ground, 
homogenized and portion of the powder was weighed 
accurately, transferred into a 50 mL brown measuring 
flask and diluted to scale with methanol. The mixture was 
sonicated for at least 20 min to aid dissolution and then 
filtered through a Whatman No 42 paper. Approximate 
dilutions were made at concentrations of 500 and 3000 
ng/mL with methanol. Excitation and emission spectra 
were recorded. 
Data analysis:  
All statistical calculations were performed with 
the Statistical Product and Service Solutions (SPSS) for 
Windows, version 10.0. Correlations were considered 
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For spectrofluorometry method, various solvent 
systems (water, methanol and acetonitrile) were 
investigated. The final decision for using methanol as the 
solvent was based on sensitivity, ease of preparation, 
suitability for drug content determination and stability 
studies. 
METHOD VALIDATION 
The validation was carried out by establishing 
specifity, linearity, intra- and inter-day precision, 
accuracy, recovery, limits of detection (LOD) and 
quantitation (LOQ) according to ICH guidance13.  
Specificity:  
All the solutions were scanned from 250 to 350 
nm at a slit width of 5.0 nm and checked for change in 
the emission at respective wavelengths. Comparison of 
the excitation and emission spectrum of atenolol in 
standard and drug formulation (Tensinor tablet) solutions 
show that the wavelength of maximum and minimum 
emission did not changed (Figs-2 and 3). According to 
the results obtained, the spectrofluorometric method is 
able to access the atenolol in presence of excipients and 
hence the method can be considered specific. 
Linearity: 
      Calibration curves were linear between the 
range 50-4000 ng/mL. Calibration plots were constructed 
for atenolol standard by plotting the concentration of 
atenolol versus spectrum emission intensity response. 
The calibration curve constructed was evaluated by its 
correlation coefficient. The correlation coefficient (r) of 
all the calibration curves were consistently greater than 
0.99. The regression equations were calculated from the 
calibration graphs, along with the standard deviations of 
the slope and intercept on the ordinate. The results are 
shown in Table-1. 
Precision and accuracy:   
      The precision of the spectrofluorometry method 
was determined by repeatability (intra-day) and 
intermediate precision (inter-day). Repeatability was 
evaluated by analyzing quality control samples six times 
per day, at three different concentrations which were 
quality control samples. The intermediate precision was 
evaluated by analyzing the same samples once daily for 
three days. The RSD of the predicted concentrations from 
the regression equation was taken as precision. The 
accuracy of this analytic method was assessed as the 
percentage relative error. For all the concentrations 
studied, intra- and inter-day RSD values were 2.97% 
and for all concentrations of atenolol the relative errors 
were 3.50%. These results were given in Table-2. 
Limits of detection (LOD) and quantification (LOQ): 
The LOD and LOQ of atenolol by the proposed 
method were determined using calibration standards13. 
LOD and LOQ values were calculated as 3.3 σ/S and 10 
σ/S, respectively, where S is the slope of the calibration 
curve and σ is the standard deviation of y-intercept of 
regression equation (n=6) (Table-1). 
Stability: 
Stability studies indicated that the samples were 
stable when kept at room temperature, 4 and -20 C 
refrigeration temperature for 6 h (short-term) and 
refrigerated at 4 and -20 C for 48 h (long-term). The 
results of these stability studies are given in Table-3, 
where the percent ratios are within the acceptance range 
of 90-110%. 
Recovery: 
      To determine the accuracy of the 
spectrofluorometry method and to study the interference 
of formulation additives, the recovery was checked as 
three different concentration levels. Analytical recovery 
experiments were performed by adding known amount of 
pure drugs to pre-analyzed samples of commercial 
dosage form. The recovery values were calculated by 
comparing concentration obtained from the spiked 
samples with actual added concentrations. These values 
are also listed in Table-4. 
     The proposed method was compared with first-
order spectrophotometric method in literature5. In this 
study, the method is based on the formation of 
phenolsulfothaline complex by derivatization. The 
concentration of atenolol was determined at 558.4 nm by 
first-order spectrophotometric method. In this study, 
linearity range was determined as 0.05-0.4 mg/mL. In 
this present work, developed spectrofluorometric method 
has small linearity range (50-4000 ng/mL).  
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Also, the suggested spectrofluorometric method 
was compared with the official method14. There was no 
significant difference between the two methods with 
respect to mean values and standard deviations at the 
95% confidence level (Table-5). As the LOQ of proposed 
the method is lower than the earlier reported works5,14. 
 
Fig-2 The excitation and emission spectrum of atenolol  
(50, 125, 250, 500, 1000, 2000, 3000 and 4000 ng/mL) 
 
Fig-3Spectrumofsolutions of Tensino tablet containing 
atenolol (500 and 3000 ng/mL) 
 
TABLE -1 
























aBased on six calibration curves, LR: Linear regression Sa: Standard deviation of intercept of regression line, Sb: Standard 
deviation of slope of regression line, R2: Coefficient of correlation, y: emission intensity, x: atenolol concentration (ng/mL), 
LOD: Limit of detection, LOQ: Limit of quantification  
 
TABLE-2 




SD : Standard deviation of six replicate determinations,  RSD: Relative standard derivation, aAverage of six replicate 



























97.9 ±2.786 -2.10 2.85 96.5 ± 2.862      -3.50 2.97 
750 741.3 ± 6.532 
 
-1.16  0.88 736.3 ± 11.09 -1.83 1.51 
3500 3481.1 ± 92.16 -0.54  2.65 3509.6 ±84.52  0.27 2.41 
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             STABILITY OF ATENOLOL IN SOLUTION 
 
SD: Standard deviation of six replicate determinations, R.S.D: Relative standard derivation, aAverage of six 
       replicate determinations 
 
TABLE 4 








SD: Standard deviation of six replicate determinations 
 
TABLE 5 
            STATISTICAL COMPARISON (F-TEST) OF THE RESULTS OBTAINED BY PROPOSED METHODS 
Commercial 
Preparation 























98.4 ± 2.832 
 




















Stability (%) Room temperature stability 
(Recovery %  SD) 
Refrigeratory stability, +4°C 
(Recovery %  SD) 
Frozen stability,  - 20°C 
(Recovery %  SD) 
 (nm) Added 
(ng/mL) 






99.2±0.639 102.3±0.073 98.2±0.709 102.1±0.046 102.2±1.625 101.5±0.227 
1000 
 
102.2±1.961 101.6±0.287 101.0±0.040 100.5±0.087 98.3±0.598 98.7±0.162 
4000 
 
102.3±0.632 98.1±0.017 101.1±3.179 99.1±0.688 101.4±0.187 101.4±0.047 
Commercial 
Preparation 

































The proposed method was found to be accurate, 
precise and easy for the determination of atenolol. The 
sample recovery in a formulation was in good agreement 
with their respective label claims. No extraction 
procedure is involved. 
The method can be used effectively, without 
separation and interference, for routine analysis of 
atenolol in pure form and its formulation and can also be 
used for dissolution or similar studies. On the other hand, 
the method is also suitable for analysis of sample during 
accelerated stability studies, routine analysis of 
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